Evaluation of Advanced Oxidation Protein Products, Prooxidant-Antioxidant Balance, and Total Antioxidant Capacity in Untreated Vitiligo Patients

Gülcan Günsat, Burhan Engin1, Özlem Balçı Ekmeği2, Zekayi Kutlubay1, Hakan Ekmeği2, Abdullah Songür1, Tuğba Keyser Üstünbaş Uzunçakmak1, Hayriye Ertem Vehid3, Server Serdaroğlu1, Yalçın Tüzün1, Hafize Uzun2

Kırklareli University, School of Health, Kırklareli, 1Cerrahpaşa Medical Faculty, Department of Dermatology, Istanbul University, 2Cerrahpaşa Medical Faculty, Department of Medical Biochemistry, Istanbul University, 3Cerrahpaşa Medical Faculty, Department of Medical Biostatistics, Istanbul University, Istanbul, Turkey

Background: Vitiligo is a chronic, common disease of unknown etiology, and oxidative stress is suggested to have a role in its etiopathogenesis. Objective: Advanced oxidation protein products (AOPPs), prooxidant-antioxidant balance (PAB), and ferric-reducing antioxidant power (FRAP) were evaluated regarding their role in the pathogenesis of vitiligo as well as their relationship with clinical presentation and disease severity, and these parameters were compared with those of healthy controls. Methods: The study included 53 patients with vitiligo and 20 healthy volunteers as the control group. AOPP level, PAB, and FRAP were determined by colorimetric methods. Results: PAB and FRAP level were significantly higher in patients with vitiligo than in healthy controls (p < 0.001). The AOPP levels in vitiligo patients were not statistically significantly higher than those in healthy controls. The Vitiligo Area Scoring Index positively correlated with disease duration (rs: 0.531, p < 0.001). Conclusion: To the best of our knowledge, this is the first report of AOPP and PAB status in vitiligo. Our results show that these parameters may play a major role in the melanocyte damage observed in vitiligo. Further studies are required to confirm the mechanisms underlying this effect. (Ann Dermatol 27(2) 178∼183, 2015)

Keywords- Advanced oxidation protein products, Ferric-reducing antioxidant power, Prooxidant-antioxidant balance, Vitiligo

INTRODUCTION

Vitiligo is a chronic, asymptomatic, usually acquired pigmentation disorder characterized by depigmented white areas on the skin and mucosal surfaces. Depigmentation is caused by melanocyte destruction that results in absence of pigment production in these areas. It affects approximately 0.1%∼8.8% of the population. The etiology remains unclear, but the theories regarding its pathogenesis include genetic, neural, cytotoxic, viral, growth factor, autoimmune, and oxidant-antioxidant theories. However, none of these theories has been proven. Recently, oxidative stress has been extensively investigated in melanocyte destruction. This reaction is a result of overproduction of reactive oxygen species (ROS) or impaired clearance of these species and characterized by an imbalance in the prooxidant and antioxidant systems. To evaluate prooxidant-antioxidant balance (PAB), the determination of both the oxidant status and the antioxidant status is often necessary. The majority of currently available methods that separately determine oxidative balance measure the total prooxidant and antioxidant capacities.
Consequently, these methods are difficult, time-consuming, expensive, and imprecise\(^5\). Here, we evaluated the PAB in vitiligo patients using a simple, rapid, and inexpensive PAB assay. Despite the well-documented role of oxidative stress in vitiligo, the determination of PAB is not a routine clinical laboratory test, mainly because of the lack of a universally accepted method\(^6\).

Some investigators have reported increased total antioxidant levels in serum, while others have reported normal levels or decreased levels of these biomarkers\(^2,8-10\). In recent years, a simple test measuring the ferric-reducing ability of plasma, the ferric-reducing antioxidant power (FRAP) assay, has been presented as a new method for evaluating antioxidant capacity\(^11\). The total antioxidant capacity (TAC) can be defined as the cumulative action of all antioxidants present in the plasma and body fluids, thus providing a composite parameter rather than the sum of measurable antioxidants\(^12\).

Clinically, the most important indicators of oxidative stress are lipid peroxidation and protein oxidation. Lipid peroxidation is particularly important in the vascular damage and melanocyte destruction in vitiligo. The addition of carbonyl groups, which are the result of proteolysis and breakage of protein side chains, are the most important components of protein oxidation\(^13,14\). Many of the published studies involve the detection of lipid peroxidation production and antioxidant levels in serum\(^2,8-10\). Studies regarding protein oxidation levels in patients with vitiligo are lacking. Recently, a new marker of protein oxidation, advanced oxidation protein products (AOPPs), has been considered for oxidant-mediated protein damage\(^12\). AOPPs are proteins that are damaged by oxidative stress, most notably albumin and its aggregates. AOPPs contain abundant dityrosines, which allow cross-linking, disulfide bridges, and carbonyl groups. AOPPs are formed primarily by chlorinated oxidants, including hypochloric acid and chloramines, which result from myeloperoxidase activity\(^16\).

Although several studies show the importance of oxidative stress in the pathogenesis of vitiligo, we were unable to find data in the literature regarding the effects of immune-mediated oxidative stress on AOPPs and PAB in vitiligo patients. Therefore, PAB, AOPP levels, and FRAP were evaluated regarding their role in the pathogenesis of vitiligo as well as their relationship with clinical presentation and disease severity, and these parameters were compared with those of healthy controls.

**MATERIALS AND METHODS**

**Subjects**

A total of 73 individuals (53 vitiligo patients, mean age: 36.87 ± 11.09 years; 20 controls, mean age: 48.00 ± 4.81 years) were included in this study. None of the patients had been treated for vitiligo. A general dermatological examination was performed for all patients. The location of vitiligo lesions was recorded. Clinical subtypes of vitiligo were defined as segmental or nonsegmental. The severity and extent of disease were calculated using the palmar unit measurement (one palmar unit represents the depigmented lesion size of the palm of the hand). According to the history provided by the patients, the Vitiligo Disease Activity Score (VIDA) was used to determine either active or stable disease. Active disease refers to an expansion of lesions and appearance of new lesions in the previous year. All patients and controls were of Turkish descent. All participants were informed about the survey and freely signed and dated the consent form. The protocol was approved by the ethics committee of the Cerrahpaşa Medical Faculty and was conducted in accordance with the Declaration of Helsinki.

**Inclusion criteria**

Eligibility was based on the following inclusion criteria: > 18 years old; either sex; not pregnant; no smoking habit; no history of an autoimmune disease, concomitant dermatological disease, or thyroid dysfunction; and no history of smoking, alcohol intake, vitamin intake, or use of anti-inflammatory or other drugs. In addition, none of the patients had undergone any therapy for 3 months prior to enrolment.

**Exclusion criteria**

The control group consisted of 20 healthy subjects selected from the hospital staff with no personal or family history of diabetes or dyslipidaemia, and had normal thyroid, hepatic, and renal function. The 2-h glucose tolerance test was used to rule out impaired glucose regulation in the healthy controls. Smokers and healthy subjects who were using drugs that were known to affect carbohydrate and lipid metabolism or oxidant and antioxidant status were also excluded from the control group.

**Laboratory analysis**

1) **Sample collection and preparation**

None of the patients and controls used any drugs for at least 24 h prior to blood collection. Clinical parameters, including routine biochemical parameters, were measured using standard protocols. Peripheral blood samples from patients with vitiligo were obtained from the Department of Dermatology in the Cerrahpaşa Medical School. Normal peripheral blood samples were obtained from the clinic.
ically healthy individuals in our medical school and in our departments. Blood samples were collected in EDTA-containing tubes and anticoagulant-free tubes after an overnight fast. After immediate centrifugation (3,000 g) for 10 min at 4°C, plasma and serum were separated in Eppendorf tubes and frozen immediately at −80°C until analysis.

2) Measurements of plasma advanced protein oxidation product levels

Spectrophotometric determinations of AOPP levels were performed using a modification of the method by Gelisgen et al.17 Samples were prepared as follows: 200 μl of plasma was diluted 1:5 in PBS, followed by the addition of 10 μl of 1.16 M KI to each tube and, finally, 20 μl of absolute acetic acid 2 min later. The absorbance of the reaction mixture was immediately read at 340 nm against a blank containing 2,000 μl of PBS, 200 μl of acetic acid, and 100 μl of KI. The linear range of chloramine-T absorbance at 340 nm occurs between 0 and 100 μmol/L. AOPP concentrations are expressed in μmol/L of chloramine-T equivalents. The coefficients of intra- and inter-assay variation were 3.1% (n=15) and 3.6% (n=15), respectively.

3) Measurement of serum ferric-reducing antioxidant power

The FRAP assay was performed according to the protocol of Benzie and Strain11, with minor modifications. To prepare the FRAP solution, 10 ml of acetate buffer (300 mM, pH=3.6) was mixed with 1 ml of 20 mM FeCl₃ dissolved in distilled water and 1 ml of 10 mM 2,4,6-tri (2-pyridyl)-s-triazine dissolved in 40 mM HCl. Next, 50 μl of serum was added to 1.5 ml of a freshly prepared FRAP solution and measured over a period of 4 min at 593 nm. Different concentrations of uric acid (0.09 ∼ 9.00 mM) were used to obtain a calibration curve on each day of the experiment. Uric acid is the primary contributor of the antioxidant capacity of serum17 and was thus used as a standard. The coefficients of intra- and inter-assay variation were 4.2% (n=15) and 6.1% (n=15), respectively.

4) Measurement of serum prooxidant-antioxidant balance

The PAB assay was performed according to the method of Alamdari et al.7, with minor modifications. Tetramethylbenzidine 3, 3', 5.5' (TMB) and TMB cations were used as oxidation-reduction indicators, due to their optical and electrochemical properties. With this approach, it is possible to measure the PAB simultaneously in one experiment by two different reaction types: one enzymatic reaction where the chromogen TMB is oxidized to a color cation by peroxides and one chemical reaction where the TMB cation is reduced to a colorless compound by antioxidants. The absorbance was measured using an enzyme-linked immunosorbent assay plate reader (ELX 800 UV; BioTek Instruments, Winooski, VT, USA) at 450 nm, with a reference wavelength of 620 or 570 nm. A standard curve was determined using the values obtained from the standard samples. PAB are expressed in arbitrary units, which correspond to the percentage of H₂O₂ in the standard solution. The coefficients of intra- and inter-assay variation were 5.3% (n=15) and 6.6% (n=15), respectively.

5) Statistical analysis

Data analysis was conducted using IBM SPSS Statistics 21.0 (IBM Co., Armonk, NY, USA). The results are reported as mean±standard deviation or median. Sex distribution was compared between the groups using Pearson chi-square analysis. Because the data were not normally distributed (Shapiro-Wilk test, p<0.05), nonparametric statistics (Mann-Whitney U tests) were used to evaluate AOPP levels and FRAP. Parametric statistics (Student t-tests) were used to evaluate PAB and age. Spearman correlation tests were used to determine correlations. Statistical significance was determined using p<0.05.

RESULTS

The demographic and clinical characteristics of the groups are shown in Table 1. According to the Pearson chi-square analysis, the distribution of sex was significantly different.

Table 1. Demographic and clinical characteristics of vitiligo patients and controls

| Characteristic                  | Vitiligo (n=53) | Control (n=20) | p-value |
|--------------------------------|----------------|---------------|---------|
| Age (y)                        | 36.87±11.09 (37.00) | 48.00±4.81 (46.50) | <0.001  |
| Sex (female/male)              | 20/33          | 14/6          | 0.018   |
| Subtypes (segmental/nonsegmental)| 6/47           | -             |         |
| VASI                           | 5.83±6.44 (3.00) | -             |         |
| VIDA (active/stable)           | 24/29          | -             |         |
| Period of disease (mo)         | 88.74±89.60 (60.00) | -             |         |

Values are presented as mean±standard deviation (median). VASI: Vitiligo Area Scoring Index, VIDA: Vitiligo Disease Activity Score.
Table 2. Oxidative stress parameters of vitiligo patients and controls

| Parameter               | Vitiligo (n = 53)          | Control (n = 20)         | p-value |
|-------------------------|---------------------------|--------------------------|---------|
| AOPPs (μmol/L chloramine T) | 55.16 ± 27.59 (42.09) | 47.37 ± 13.32 (46.04) | 0.853   |
| FRAP (mmol/L uric acid)   | 0.17 ± 0.05 (0.16)     | 0.13 ± 0.03 (0.12)     | <0.001  |
| PAB (AU)                 | 41.79 ± 18.79 (42.95) | 17.29 ± 12.80 (19.51) | <0.001  |

Values are presented as mean±standard deviation (median). AOPPs: advanced protein oxidation products, FRAP: ferric-reducing antioxidant power, PAB: prooxidant-antioxidant balance, AU: arbitrary units that correspond to the percentage of H₂O₂ in the standard solution.

Table 3. Oxidative stress parameters of vitiligo patients with active or stable disease

| Parameter               | Active patients (n = 24)         | Stable patients (n = 29)            | p-value |
|-------------------------|----------------------------------|------------------------------------|---------|
| AOPPs (μmol/L chloramine T) | 52.10 ± 29.03 (35.05) | 57.69 ± 26.58 (52.84) | 0.300   |
| FRAP (mmol/L uric acid)   | 0.16 ± 0.04 (0.17)     | 0.17 ± 0.01 (0.15)     | 0.680   |
| PAB (AU)                 | 40.83 ± 16 (41.90)     | 42.56 ± 20.65 (44.44) | 0.742   |

Values are presented as mean±standard deviation (median). AOPPs: advanced protein oxidation products, FRAP: ferric-reducing antioxidant power, PAB: prooxidant-antioxidant balance, AU: arbitrary units correspond to the percentage of H₂O₂ in the standard solution.

Fig. 1. Relationship between the Vitiligo Area Scoring Index (VASI) and disease duration in patients with vitiligo.

DISCUSSION

Human skin serves as an interface between the environment and the body. It is constantly exposed to a broad array of physical, chemical, and biological agents, many of which either are inherent oxidants or catalyze the generation of ROS. Oxidative stress is believed to be involved in the pathogenesis of inflammatory skin diseases. The present study demonstrated that FRAP and PAB were significantly higher in patients with vitiligo than in healthy controls. Although the AOPP levels were higher in the patient group, this was not statistically significant. These results indicate that increased FRAP, PAB, and AOPP levels are likely associated with oxidative stress in vitiligo. Melanocyte damage in vitiligo pathogenesis remains unclear. A single mechanism is not responsible for all cases of melanocyte damage in vitiligo, and oxidative stress is considered a possible pathogenic event in melanocyte loss. Decreased antioxidant levels and increased prooxidant levels may play important roles in the damage of melanocytes observed in vitiligo patients. PAB was higher in vitiligo patients in the present study. One possible explanation for this might be impaired PAB. A shift in this equilibrium likely contributes to the pathogenesis of vitiligo. The PAB assay is a simple, rapid, and inexpensive method that can measure the prooxidant burden and the antioxidant capacity in one assay. This ratio can be used as an additive marker of oxidative stress in patients with vitiligo as in patients with Behçet disease (BD). Based on our re-
sults, PAB may be the initial pathogenic event in melanocyte degeneration. Nevertheless, we suggest that the PAB assay may be useful as a risk predictor in diseases such as vitiligo and could help to identify patients with high oxidative stress to facilitate early preventive interventions for melanocyte damage.

Several investigators have assessed the capacity of antioxidative defense systems in vitiligo. Boisseau-Garsaud et al. reported that patients with vitiligo had significantly lower TAC than controls. Perhaps, antioxidant molecules cannot be used actively within the white areas. Clinically, it is also difficult to determine the active period of vitiligo. In contrast, we found that both PAB and FRAP were higher, but not correlated, in vitiligo patients. It is unclear whether high FRAP indicates a source of unused antioxidants or up-regulated antioxidant production as a response to oxidative stress. We consider oxidative stress as a causative factor in patients with vitiligo. However, further studies are required to confirm the mechanisms underlying this effect.

AOPPs have been proposed as a possible marker of oxidative injury that originate as a result of the action of free radicals on proteins. Although AOPP levels were higher, this was not statistically significant. AOPP levels have been reported to be significantly increased in active periods of patients with BD compared with those in healthy controls and in the remission periods of patients with BD. Previous studies (both human and experimental) have demonstrated that older people have higher AOPP levels. Despite an older age in the control group, AOPP levels were higher (statistically insignificant) in patients with vitiligo in the present study. This might partially support the role of oxidative stress in vitiligo pathogenesis. In addition, high AOPP levels are indicative of an increase in oxidative stress and can cause direct oxidative damage to proteins in vitiligo patients. These oxidized proteins may partially contribute to the development of melanocyte loss. As a disease characterized with oxidative stress-autoimmunity-mediated melanocyte loss, the pathogenesis of vitiligo is unclear. Our results indicate that oxidative stress might play a role in the etiopathogenesis of vitiligo, because of the increased serum PAB and AOPP. PAB may be especially useful in this regard because of its measurement is rapid, easy, and cost-effective in laboratories. Thus, we recommend that PAB measurement be more widely used in clinical practice. FRAP should be reevaluated in future clinical trials in the early stage of the disease. Also, FRAP is important in treated patients with vitiligo due to changes in the antioxidant capacity as a result of treatment.

REFERENCES

1. Denli Y, Acar MA, Sönmezoglu Maraklı S, Yücel A. Vitiligo. Disorders of pigmentation. In: Tüzün Y, Gürer MA, Serdarolu S, Oğuz O, Aksungur V, editors. Dermatology. 3rd ed. Istanbul: Nobel Publishing, 2008:1463-1490.
2. Kutlubay Z, Uzuncakmak TK, Engin B, Tüzün Y. Vitiligo and oxidative stress. J Turk Acad Dermatol 2011;5:115-41.
3. Schallreuter KU, Bahadoran P, Picardo M, Slominski A, Elsässer YE, Kemn EH, et al. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol 2008;17:139-140; discussion 141-160.
4. Karaca Ş, Güder H. Antioxidant system in dermatology. Turk J Dermatol 2009;3:32-39.
5. Parizadeh SM, Azarpazhooh MR, Moohebati M, Nematy M, Ghayour-Mobarhan M, Tavallaie S, et al. Simvastatin therapy reduces prooxidant-antioxidant balance: results of a placebo-controlled cross-over trial. Lipids 2011;46:333-340.
6. Laddha NC, Dwivedi M, Mansuri MS, Gani AR, Ansarullah M, Ramachandran AV, et al. Vitiligo: interplay between oxidative stress and immune system. Exp Dermatol 2013;22:245-250.
7. Alamdari DH, Ghayour-Mobarhan M, Tavallaie S, Parizadeh MR, Moohebati M, Ghafouri F, et al. Prooxidant-antioxidant balance as a new risk factor in patients with angiographically defined coronary artery disease. Clin Biochem 2008;41:375-380.
8. Arican O, Kurutas EB. Oxidative stress in the blood of patients with active localized vitiligo. Acta Dermatovenereol Alp Pannonica Adriat 2008;17:12-16.
9. Jain A, Mal J, Mehndiratta V, Chander R, Patra SK. Study of oxidative stress in vitiligo. Indian J Clin Biochem 2011;26:78-81.
10. Koca R, Armutcu F, Altintay HC, Gürel A. Oxidant-antioxidant enzymes and lipid peroxidation in generalized vitiligo. Clin Exp Dermatol 2004;29:406-409.
11. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem 1996;239:70-76.
12. Karacay O, Sepici-İncel A, Karcaaltincaba D, Sahin D, Yalvaç S, Akyl M, et al. A quantitative evaluation of total antioxidant status and oxidative stress markers in preclampsia and gestational diabetic patients in 24-36 weeks of gestation. Diabetes Res Clin Pract 2010;89:231-238.
13. Breusing N, Grune T. Biomarkers of protein oxidation from a chemical, biological and medical point of view. Exp Gerontol 2010;45:733-737.
14. Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo
R. Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta 2003;329:23-38.
15. Zhou Q, Wu S, Jiang J, Tian J, Chen J, Yu X, et al. Accumulation of circulating advanced oxidation protein products is an independent risk factor for ischaemic heart disease in maintenance haemodialysis patients. Nephrology (Carlton) 2012;17:642-649.
16. Cakatay U, Kayali R, Uzun H. Relation of plasma protein oxidation parameters and paraoxonase activity in the ageing population. Clin Exp Med 2008;8:51-57.
17. Gelisgen R, Genc H, Kayali R, Oncul M, Benian A, Guralp O, et al. Protein oxidation markers in women with and without gestational diabetes mellitus: a possible relation with paraoxonase activity. Diabetes Res Clin Pract 2011;94:404-409.
18. Glassman SJ. Vitiligo, reactive oxygen species and T-cells. Clin Sci (Lond) 2011;120:99-120.
19. Ozyazgan S, Andican G, Erman H, Tuzcu A, Uzun H, Onal B, et al. Relation of protein oxidation parameters and disease activity in patients with Behçet’s disease. Clin Lab 2013;59:819-825.
20. Schallreuter KU. Successful treatment of oxidative stress in vitiligo. Skin Pharmacol Appl Skin Physiol 1999;12:132-138.
21. Akoglu G, Emre S, Metin A, Akbas A, Yorulmaz A, Isikoglu S, et al. Evaluation of total oxidant and antioxidant status in localized and generalized vitiligo. Clin Exp Dermatol 2013;38:701-706.
22. Boisseau-Garsaud AM, Garsaud P, Lejoly-Boisseau H, Robert M, Quist D, Arveiler B. Increase in total blood antioxidant status and selenium levels in black patients with active vitiligo. Int J Dermatol 2002;41:640-642.